RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to outsmart tough lymphoma
Disease control Recruiting nowThis trial tests a combination of two drugs, epcoritamab and ibrutinib, for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Epcoritamab helps immune cells attack lymphoma cells, while ibrutinib blocks signals that help cancer ce…
Matched conditions: RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo therapy takes on tough lymphoma
Disease control Recruiting nowThis study tests a combination of two treatments—zanubrutinib (a targeted drug) and lisocabtagene maraleucel (a CAR T-cell therapy)—for people with Richter's syndrome, an aggressive lymphoma that can develop from chronic lymphocytic leukemia. The goal is to see if this combo can …
Matched conditions: RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Aseel Alsouqi • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental CAR T-Cell combo aims to stop lymphoma relapse after transplant
Disease control Recruiting nowThis early-phase trial is testing whether giving special immune cells (CMV-specific CD19-CAR T cells) along with a vaccine (CMV-MVA triplex) after a stem cell transplant can safely help prevent B-cell non-Hodgkin lymphoma from returning. About 15 people with intermediate or high-…
Matched conditions: RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo may help more lymphoma patients reach potentially curative CAR-T
Disease control Recruiting nowThis study tests whether giving two drugs, golcadomide and rituximab, before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to keep the disease in check so more patients can qualify for…
Matched conditions: RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC